Physician profile
Samuel Garrett
NPI 1699745042
$403.25
in general payments reported to CMS, 2019-2025
13 companies · $62.26 in 2025
The $62.26 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.09 · 2020: $21.43 · 2021: $98.82 · 2022: $79.58 · 2024: $74.07 · 2025: $62.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $98.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $63.40 | 2022 | |
| Amgen INC. | $38.28 | 2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $27.09 | 2019 | |
| Thea Pharma INC. | $23.98 | 2025 | Iyuzeh |
| Dompe US, INC. | $22.20 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.43 | 2020 | |
| Harrow Eye, LLC | $19.82 | 2024 | Vevye |
| Alcon Vision LLC | $19.41 | 2024 | Clareon |
| Kala Pharmaceuticals, INC. | $17.80 | 2019 | |
| Bausch & Lomb Americas INC. | $17.51 | 2024 | Xiidra, Miebo |
| Abbvie INC. | $17.33 | 2024 | |
| Allergan, INC. | $16.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.